{"id":17785,"date":"2022-10-21T18:19:15","date_gmt":"2022-10-21T12:49:15","guid":{"rendered":"https:\/\/kuvera.in\/blog\/?p=17785"},"modified":"2022-10-21T18:19:15","modified_gmt":"2022-10-21T12:49:15","slug":"cadila-share-price-history-and-analysis","status":"publish","type":"post","link":"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/","title":{"rendered":"Cadila Share Price History and Analysis"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_40 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" area-label=\"ez-toc-toggle-icon-1\"><label for=\"item-69d88d25398e5\" aria-label=\"Table of Content\"><span style=\"display: flex;align-items: center;width: 35px;height: 30px;justify-content: center;direction:ltr;\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/label><input  type=\"checkbox\" id=\"item-69d88d25398e5\"><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#About_Cadila\" title=\"About Cadila\">About Cadila<\/a><ul class='ez-toc-list-level-3'><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#Companys_History\" title=\"Company\u2019s History\">Company\u2019s History<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#Top_Shareholder\" title=\"Top Shareholder\">Top Shareholder<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#Highlights_From_Cadila_Healthcare_Ltds_Latest_Quarterly_Results_-_Q1_FY_23\" title=\"Highlights From Cadila Healthcare Ltd\u2019s Latest Quarterly Results &#8211; Q1 FY 23\">Highlights From Cadila Healthcare Ltd\u2019s Latest Quarterly Results &#8211; Q1 FY 23<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#Business_Highlights\" title=\"Business Highlights\">Business Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#Managements_Take\" title=\"Management\u2019s Take\">Management\u2019s Take<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#Why_Should_You_Invest_in_Cadila_Healthcare_Ltd\" title=\"Why Should You Invest in Cadila Healthcare Ltd.?\">Why Should You Invest in Cadila Healthcare Ltd.?<\/a><ul class='ez-toc-list-level-4'><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#FAQ_On_Cadila_Healthcare_Ltd\" title=\"FAQ On Cadila Healthcare Ltd\">FAQ On Cadila Healthcare Ltd<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#What_is_Cadila_Healthcare_Ltds_share_price_and_what_are_the_returns_for_Cadila_share_Price\" title=\"What is Cadila Healthcare Ltd\u2019s share price, and what are the returns for Cadila share Price?\">What is Cadila Healthcare Ltd\u2019s share price, and what are the returns for Cadila share Price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#What_are_the_52-week_highs_and_lows_of_Cadila_Share_Price\" title=\"What are the 52-week highs and lows of Cadila Share Price?\">What are the 52-week highs and lows of Cadila Share Price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#What_are_the_key_metrics_to_analyse_Cadila_Healthcare_Ltds_Share_Price\" title=\"What are the key metrics to analyse Cadila Healthcare Ltd\u2019s Share Price?\">What are the key metrics to analyse Cadila Healthcare Ltd\u2019s Share Price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#Who_are_the_peers_of_Cadila_Healthcare_Ltd\" title=\"Who are the peers of Cadila Healthcare Ltd?\">Who are the peers of Cadila Healthcare Ltd?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#What_is_the_market_cap_of_Cadila_Healthcare_Ltd\" title=\"What is the market cap of Cadila Healthcare Ltd?\">What is the market cap of Cadila Healthcare Ltd?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#Interested_in_how_we_think_about_the_markets\" title=\"Interested in how we think about the markets?\">Interested in how we think about the markets?<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2 style=\"color: black; font-size: 20px;\"><span class=\"ez-toc-section\" id=\"About_Cadila\"><\/span>About Cadila<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\"><a href=\"https:\/\/kuvera.in\/stocks\/cadila-healthcare-ltd\">Cadila Healthcare Limited<\/a>, incorporated and headquartered in India, operates as an integrated pharmaceutical corporation with operations spanning the whole value chain of pharmaceutical product research, development, production, marketing, and distribution. The company&#8217;s product line includes active pharmaceutical ingredients (API) and human formulations. The company&#8217;s <a href=\"https:\/\/kuvera.in\/stocks\/listing\/all\">stock<\/a> is listed on the <a href=\"https:\/\/kuvera.in\/blog\/national-stock-exchangense\/\">National Stock Exchange of India Limited (NSE)<\/a> and the <a href=\"https:\/\/kuvera.in\/blog\/what-are-nse-and-bse\/\">Bombay Stock Exchange Limited (BSE)<\/a>.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><a href=\"https:\/\/kuvera.in\/fixed-deposit\/all\"><img loading=\"lazy\" class=\"aligncenter wp-image-14483 size-large\" src=\"https:\/\/kuvera.in\/blog\/wp-content\/uploads\/2022\/08\/fd-blog-01-1-1024x334.jpg\" sizes=\"(max-width: 640px) 100vw, 640px\" srcset=\"https:\/\/kuvera.in\/blog\/wp-content\/uploads\/2022\/08\/fd-blog-01-1-1024x334.jpg 1024w, https:\/\/kuvera.in\/blog\/wp-content\/uploads\/2022\/08\/fd-blog-01-1-300x98.jpg 300w, https:\/\/kuvera.in\/blog\/wp-content\/uploads\/2022\/08\/fd-blog-01-1-768x250.jpg 768w, https:\/\/kuvera.in\/blog\/wp-content\/uploads\/2022\/08\/fd-blog-01-1-150x49.jpg 150w, https:\/\/kuvera.in\/blog\/wp-content\/uploads\/2022\/08\/fd-blog-01-1.jpg 1080w\" alt=\"kuvera-fixed-deposit-online\" width=\"640\" height=\"209\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">The company&#8217;s research and development objectives include New Chemical Entities (NCE), biologics, vaccines, speciality and complicated generic formulations, and API process development. The company has a global presence and sells its products in the United States, India, and Europe, as well as growing markets in Latin America, the Asia-Pacific region, and Africa. Modern, cost-effective, and regulatory-compliant manufacturing facilities assure a constant supply of high-quality products at the most competitive pricing to the company&#8217;s global clients.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">The company is one of the leading innovation-driven pharmaceutical companies in India, with a presence across the entire pharmaceutical value chain, including R&amp;D, manufacturing, marketing, and sales of finished dosage human formulations (generics, branded generics, and speciality formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products, and consumer wellness products. Innovation is the company&#8217;s backbone since it enables the ongoing availability of new products for various businesses, hence ensuring commercial viability.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h3 style=\"color: black; font-size: 20px;\"><span class=\"ez-toc-section\" id=\"Companys_History\"><\/span>Company\u2019s History<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">Cadila Healthcare Ltd is a well-known, research-focused, technology-driven pharmaceutical company that focuses on biotechnology, formulations, and Active Pharmaceutical Ingredients. They are a multinational pharmaceutical company with headquarters in India. They have production plants in Gujarat in Ahmedabad, Ankleshwar, and Vadodara, in Goa at Ponda, in Maharashtra at Raigad, and in Himachal Pradesh at Solan.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">Cadila Healthcare Ltd, the main company of Zydus Cadila Group, was established in May 1995 and went public in July 1996. Pharmaceuticals, including human formulations, veterinary formulations, bulk drugs, diagnostics, herbal goods, skin care products, and over-the-counter products, are part of the company&#8217;s operations.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">In 1996, the company formed a strategic agreement with Gulin Pharma of China and marketed the anti-malarial drug Falcigo in India. In May of 2000, the company purchased Recon Ltd&#8217;s formulation business, strengthening its position in the southern region. In 2001, they purchased German Remedies, the largest merger and acquisition in the Indian pharmaceutical industry, and in the same year, they formed a joint venture with Onconova, a company based in the United States, for collaborative research in the field of oncogenomics.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">In April 2002, the company purchased Banyan Chemicals, a Vadodara-based firm with an FDA-approved facility in the United States. German Remedies, Recon Healthcare, Zoom Properties, and Zydus Pathline amalgamated with the business in 2003. In addition, they purchased Alpharma France, which led the group&#8217;s operations in France. In the same year, the company became Schering AG&#8217;s &#8220;Partner of Choice&#8221; for manufacturing and marketing its products in India.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">In November 2004, the company formed a strategic alliance with the Italian Zambon Group to expand its contract manufacturing opportunities. In the same year, the company signed a long-term strategic agreement with Boehringer Ingelheim India Ltd, a wholly-owned subsidiary of Boehringer Ingelheim (BI), to produce and distribute BI&#8217;s products in India.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">In 2005, the company formed a strategic agreement with Mallinckrodt Pharmaceuticals Generics, a business subsidiary of Tyco Healthcare, in order to promote the company&#8217;s product under a joint label. In the same year, the company formed a joint venture with Mayne Pharma of Australia to manufacture generic injectable cytotoxic (anti-cancer) drugs and active pharmaceutical ingredients (API) for international markets.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">In 2005-2006, the company created a 50:50 joint venture with one of India&#8217;s leading biotech companies, Bharat Serums and Vaccines Ltd. (BSV), to develop, manufacture, and market a non-infringing and patented Novel Drug Delivery System (NDDS) of an approved anti-cancer medicine for worldwide markets.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">During the 2006-2007 fiscal year, the company engaged in a share purchase agreement to buy a 97.95% ownership interest in Liva Healthcare Ltd., which manufactures and sells formulas. In Sikkim, a greenfield facility for Solid Oral Dosage Forms was constructed primarily for the domestic market. They also established a lyophilisation unit at the Moraiya plant with an annual capacity of seven and a half million doses to serve both the Indian and international markets.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">During the 2007-2008 fiscal year, the business revamped its formulation division, Alidac, and introduced two new sub-divisions, Corza and Fortiza. In addition, they entered the nutraceutical market and founded Zydus Nutriva, a new division. The injectables factory in Moraiya has been upgraded, and its production facility in Ankleshwar has been extended.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">To develop their branded business in Brazil, Zydus Healthcare Brasil Ltd, a wholly-owned subsidiary of the corporation, purchased 100% of the shares of Brazilian pharmaceutical company Quimica e Farmaceutica Nikkho Do Brasil Ltda. In addition, Zydus Pharmaceuticals Inc., Japan, a wholly-owned subsidiary of the corporation, bought 100% of the shares of Nippon Universal Pharmaceuticals Co., Ltd., a Japanese company that manufactures and markets pharmaceutical goods in Japan.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">In February 2008, the company and Swedish Karo Bio entered into a three-year strategic partnership in the field of medication discovery and development. The company is in the midst of constructing a fine chemical facility in Dabhasa at a cost of approximately Rs 200 million, which will begin production in the 2008-2009 fiscal year.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">In May 2008, the company entered the Spanish market by purchasing a 100% ownership interest in Laboratories Combix. In June 2008, the business would acquire a 70% majority stake in Simayla Pharmaceuticals of South Africa through its wholly-owned subsidiary, Zydus Healthcare SA Pty Ltd.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">The company&#8217;s Consumer Products Division would be transferred to Carnation Nutra Analogue Foods Ltd, a subsidiary of Cadila Healthcare, and Zydus Hospital and Medical Research Pvt Ltd will be merged with the company.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">Using monoclonal antibodies, the company entered into an agreement with WHO in August 2008 to examine the possibility of a collaboration in the development of a cocktail for the treatment of rabies.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h3 style=\"color: black; font-size: 20px;\"><span class=\"ez-toc-section\" id=\"Top_Shareholder\"><\/span>Top Shareholder<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">Below is a list of the top shareholders of Cadila Share Price as of June 2022.<\/span><\/p>\n<p>&nbsp;<\/p>\n<table style=\"width: 100%;\" border=\"1.5\">\n<tbody>\n<tr>\n<td><b>Shareholder<\/b><\/td>\n<td style=\"text-align: center;\"><b>No. of Shares\u00a0<\/b><\/td>\n<td style=\"text-align: center;\"><b>Shareholding (%)<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Zydus Family Trust<\/span><\/td>\n<td style=\"text-align: center;\"><span style=\"font-weight: 400;\">75,87,88,706<\/span><\/td>\n<td style=\"text-align: center;\"><span style=\"font-weight: 400;\">74.96%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Kotak Flexicap Fund<\/span><\/td>\n<td style=\"text-align: center;\"><span style=\"font-weight: 400;\">2,53,16,795<\/span><\/td>\n<td style=\"text-align: center;\"><span style=\"font-weight: 400;\">2.50%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Life Insurance Corporation of India<\/span><\/td>\n<td style=\"text-align: center;\"><span style=\"font-weight: 400;\">6,42,67,147<\/span><\/td>\n<td style=\"text-align: center;\"><span style=\"font-weight: 400;\">6.35%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Resident Individuals holding nominal share capital up to Rs. 2 Lakhs<\/span><\/td>\n<td style=\"text-align: center;\"><span style=\"font-weight: 400;\">6,84,41,694<\/span><\/td>\n<td style=\"text-align: center;\"><span style=\"font-weight: 400;\">6.76%<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<p><b>Top Management<\/b><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">Below is a list of Cadila top management as of June 2022<\/span><\/p>\n<table style=\"width: 100%;\" border=\"1.5\">\n<tbody>\n<tr>\n<td><b>Name\u00a0<\/b><\/td>\n<td><b>Designation<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Mr. Pankaj R Patel\u00a0<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Chairman<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Mr. Ganesh N Nayak<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Executive Director<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Ms. Apurva S Diwanji<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Independent Director<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Mr. Nitin R Desai<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Independent Director<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Ms. Dharmishtaben N Raval<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Independent Woman Director<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Dr. Sharvil P Patel<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Managing Director<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Mr. Mukesh Patel<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Non-Executive Director<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Mr. Nitin D Parekh\u00a0<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Chief Financial Officer<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Mr. Dhaval N Soni<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Co. Secretary &amp; Comp. Officer<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<h3 style=\"color: black; font-size: 20px;\"><span class=\"ez-toc-section\" id=\"Highlights_From_Cadila_Healthcare_Ltds_Latest_Quarterly_Results_-_Q1_FY_23\"><\/span>Highlights From Cadila Healthcare Ltd<span style=\"font-weight: 400;\">\u2019<\/span>s Latest Quarterly Results &#8211; Q1 FY 23<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The operational revenue was Rs. 40,727 million, a 2% increase over the previous year.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Investments in research and development (R&amp;D) for the quarter totalled Rs. 2,842 million (or 7.0% of revenue).<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The reported EBITDA for the quarter was 8,330 million rupees, a decrease of 14% year-over-year. The EBITDA margin for the quarter was 20.5 per cent.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The reported net profit for the quarter was Rs. 5,183 million, a 12% decrease year-over-year. Adjusted for unusual items and loss from discontinued activities, the Net Profit for the quarter decreased by 11% year-over-year to Rs. 5,295 million.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The Organic CAPEX for the quarter was Rs 2,828 million.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Net cash as of 30 June 2022 is Rs 5,628 million<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Business_Highlights\"><\/span>Business Highlights<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>&nbsp;<\/p>\n<p><strong>Formulation Business<\/strong><\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Revenues of Rs. 11,251 million decreased by 17% year-over-year. Excluding sales of COVID-related goods, the generics portfolio, and products that were sold, the branded prescription business climbed by 9 per cent year-over-year. The business was responsible for 29% of the total revenue.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Increased market share and ranking in core therapies such as cardiovascular, gynaecological, respiratory, and pain management on a year-over-year basis throughout the quarter\u00a0<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Lipaglyn\u00ae, Cadila\u2019s first NCE brand, is currently the 66th largest brand in IPM, a sequential improvement of 13 spots.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Cadilla maintained a leadership position in the Nephrology segment while gaining many positions in Oncology to become one of the top two players in India.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Consumer Wellness Business<\/strong><\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Reported revenues of Rs 6,916 million, up 18% year-over-year. The business contributed 17% of total company revenue. They were able to re-recruit consumers for summer-heavy brands like Glucon-D and Nycil due to the timely arrival of summer and the expansion of distribution reach. This contributed to double-digit growth for these two iconic brands.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>US formulations Business<\/strong><\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Registered revenues of Rs. 15,592 million, up 9% y-o-y and 10% q-o-q. The business accounted for forty per cent of total revenue.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">In constant currency terms, the company registered revenue was $ 202 million.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Submitted eight ANDAs and was granted approval for seven new products (including one tentative approval) throughout the quarter.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">During the quarter, three filings were designated as Competitive Generic Therapies (CGT), while one approval was for the first cycle.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Eight new goods were introduced throughout the quarter.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">On the Specialty front, commercial shipment of Nulibry\u00ae has begun (Fosdenopterin for Injection).<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Emerging Markets (EM) Pharmaceuticals Business<\/strong><\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The company maintained its growth momentum and reported revenues of Rs. 3,155 million, up 14% year-over-year. The business was responsible for 8% of the total revenue.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">During the quarter, growth was widespread across the majority of geographies.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Europe&#8217;s formulations Business<\/strong><\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Revenues of Rs. 614 million were reported, up 3% year-over-year. The business was responsible for 2% of total revenue.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>API Business<\/strong><\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Revenues of Rs. 1,224 million were down 10% year-over-year. The business was responsible for 3% of total revenue.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Alliances and Others<\/strong><\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Reported revenues of Rs. 477 million, down 6% year-over-year. The business was responsible for 1% of total revenue.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<h3 style=\"color: black; font-size: 20px;\"><span class=\"ez-toc-section\" id=\"Managements_Take\"><\/span>Management\u2019s Take<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">Dr. Sharvil Patel Managing Director, Zydus Lifesciences Limited said, \u201cWe are encouraged by our stable Q1 FY23 performance, particularly with the rebound in US business even as Consumer Wellness and Emerging Markets sustained growth momentum. India branded formulations business, adjusting for COVID impact delivered healthy growth and we expect to improve further. Focus on cost optimization helped us sustain 20% plus EBITDA margins amid input cost pressures. We continue to advance our innovation pipeline to build a strong foundation for the future. &#8220;<\/span><\/p>\n<p>&nbsp;<\/p>\n<h3 style=\"color: black; font-size: 20px;\"><span class=\"ez-toc-section\" id=\"Why_Should_You_Invest_in_Cadila_Healthcare_Ltd\"><\/span>Why Should You Invest in Cadila Healthcare Ltd.?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">According to NITI AAYOG, the Indian healthcare industry is anticipated to reach $372 billion by 2022, driven by rising incomes, better health awareness, lifestyle disorders, and expanding insurance coverage. Healthcare is now one of India&#8217;s top industries in terms of both revenue and jobs.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">Hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment are included in healthcare. Primary care, secondary care, and tertiary care are the three major components of the Indian healthcare delivery system.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">Primary care is the population&#8217;s initial point of contact with healthcare service providers. For instance, Sub-center (SC), Primary Health Centres (PHCs), and Community Health Centres (CHCs) are more pertinent to rural areas than Sub-center (SC).<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">Secondary care encompasses both inpatient and outpatient medical services, as well as straightforward surgical procedures. For instance, district hospitals and mid-sized hospitals.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">The third level of the nation&#8217;s healthcare delivery system is tertiary care. These hospitals are infrastructure for specialized healthcare consultation. Hospitals with single or many specialities are examples.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">In spite of the fact that both the public and private sectors offer healthcare services in urban and rural areas, people choose private hospitals over public hospitals for the treatment of disease, illness, and sickness. Therefore, let&#8217;s examine Zydus Lifesciences and its performance throughout time.<\/span><\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><strong>Operating cash flow ratio:<\/strong> It gauges a company&#8217;s ability to meet its short-term financial obligations using the cash generated from operating activities. Its operating cash flow was Rs 1,310.70 Cr.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><strong>Financial Stability:<\/strong> The balance sheets of healthcare organizations typically reflect significant debt loads and little equity capital. Therefore, the Debt to Equity ratio is essential for evaluating the sustainability of a corporation. The debt-to-equity ratio of 0.20 for Zydus Lifesciences is a positive sign for the company.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><strong>EPS growth:<\/strong> Investors should check that the EPS figure is growing faster than revenue numbers since this implies that the company&#8217;s management is becoming more efficient. The EPS growth for Zydus Lifesciences was -41.88%, which is negative for the company.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><strong>Operating profit margin:<\/strong> It influences the prospective earnings of a company. Zydus Lifesciences has an OPM of 24.01%, which is a positive indicator of profitability. It measures how well a company manages its basic overhead expenses and other operational expenses.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\"><strong>ROE:<\/strong> Zydus Lifesciences has a mediocre return on equity of 6.60%. ROE is a significant financial metric for hospitals and healthcare organizations due to its quick expansion and growth. Therefore, <a href=\"https:\/\/kuvera.in\/blog\/what-is-return-on-equity\/\">ROE<\/a> assesses the profitability of a company&#8217;s utilization of shareholder funds.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<h4 style=\"color: black; font-size: 20px;\"><span class=\"ez-toc-section\" id=\"FAQ_On_Cadila_Healthcare_Ltd\"><\/span>FAQ On Cadila Healthcare Ltd<span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\">\n<h4 style=\"color: black; font-size: 18px;\"><span class=\"ez-toc-section\" id=\"What_is_Cadila_Healthcare_Ltds_share_price_and_what_are_the_returns_for_Cadila_share_Price\"><\/span>What is Cadila Healthcare Ltd\u2019s share price, and what are the returns for Cadila share Price?<span class=\"ez-toc-section-end\"><\/span><\/h4>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">Cadila\u00a0 share price is INR 415.35\u00a0 as of\u00a0 14th October 2022. Cadila Healthcare Ltd has provided a return of approximately -15.57% in the past five years as of 14th October 2022.<\/span><\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\">\n<h4 style=\"color: black; font-size: 18px;\"><span class=\"ez-toc-section\" id=\"What_are_the_52-week_highs_and_lows_of_Cadila_Share_Price\"><\/span>What are the 52-week highs and lows of Cadila Share Price?<span class=\"ez-toc-section-end\"><\/span><\/h4>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">As on 14th October 2022 Cadila Share Price are:\u00a0<\/span><\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><span style=\"font-weight: 400;\">52-wk high<\/span> <span style=\"font-weight: 400;\">Rs 552<\/span><\/li>\n<li><span style=\"font-weight: 400;\">52-wk low<\/span> <span style=\"font-weight: 400;\">Rs 319<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\">\n<h4 style=\"color: black; font-size: 18px;\"><span class=\"ez-toc-section\" id=\"What_are_the_key_metrics_to_analyse_Cadila_Healthcare_Ltds_Share_Price\"><\/span>What are the key metrics to analyse Cadila Healthcare Ltd\u2019s Share Price?<span class=\"ez-toc-section-end\"><\/span><\/h4>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Key metrics to analyse any share price are: a 52-week high, a 52-week low, a 1-year return, a 5-year return, etc.\u00a0<\/span><\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\">\n<h4 style=\"color: black; font-size: 18px;\"><span class=\"ez-toc-section\" id=\"Who_are_the_peers_of_Cadila_Healthcare_Ltd\"><\/span>Who are the peers of Cadila Healthcare Ltd?<span class=\"ez-toc-section-end\"><\/span><\/h4>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Peers of Cadila Healthcare Ltd include <a href=\"https:\/\/kuvera.in\/stocks\/sun-pharma-advanced-research-co-ltd\">Sun Pharma<\/a>, <a href=\"https:\/\/kuvera.in\/stocks\/cipla-ltd\">Cipla<\/a>, <a href=\"https:\/\/kuvera.in\/stocks\/dr-reddy-s-laboratories-ltd\">Dr Reddys Lab<\/a>, <a href=\"https:\/\/kuvera.in\/stocks\/abbott-india-ltd\">Abbott India<\/a> etc.<\/span><\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\">\n<h4 style=\"color: black; font-size: 18px;\"><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_of_Cadila_Healthcare_Ltd\"><\/span>What is the market cap of Cadila Healthcare Ltd?<span class=\"ez-toc-section-end\"><\/span><\/h4>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">The market cap of Cadila Healthcare Ltd is INR 42.04 Thousand crores as of 14th October 2022.<\/span><br \/>\n&nbsp;<\/p>\n<h4 style=\"color: black; font-size: 18px;\"><span class=\"ez-toc-section\" id=\"Interested_in_how_we_think_about_the_markets\"><\/span>Interested in how we think about the markets?<span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p>&nbsp;<\/p>\n<p>Read more:\u00a0<a href=\"https:\/\/kuvera.in\/blog\/category\/zen-and-the-art-of-investing\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Zen And The Art Of Investing<\/strong><\/a><\/p>\n<p>Watch\/hear on YouTube:<\/p>\n<p>&nbsp;<\/p>\n<p style=\"padding-left: 40px;\">\n<style>.embed-container { position: relative; padding-bottom: 56.25%; height: 0; overflow: hidden; max-width: 100%; } .embed-container iframe, .embed-container object, .embed-container embed { position: absolute; top: 0; left: 0; width: 100%; height: 100%; }<\/style>\n<\/p>\n<div class=\"embed-container\"><iframe src=\"https:\/\/www.youtube.com\/embed\/f7yfzUhQDiM\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><span data-mce-type=\"bookmark\" style=\"display: inline-block; width: 0px; overflow: hidden; line-height: 0;\" class=\"mce_SELRES_start\">\ufeff<\/span><\/iframe><\/div>\n<p>&nbsp;<\/p>\n<p>Start investing through a platform that brings goal planning and investing to your fingertips. Visit\u00a0<a href=\"https:\/\/app.kuvera.in\/\">Kuvera.in<\/a>\u00a0to discover\u00a0<a href=\"https:\/\/kuvera.in\/blog\/direct-plans-better\/\">Direct Plans<\/a>\u00a0and\u00a0<a href=\"https:\/\/app.kuvera.in\/explore\/fixed-deposit\/c\/all\">Fixed Deposits<\/a>\u00a0and\u00a0<a href=\"https:\/\/kuvera.in\/user\/login\">start investing today.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>About Cadila &nbsp; Cadila Healthcare Limited, incorporated and headquartered in India, operates as an integrated pharmaceutical corporation with operations spanning the whole value chain of pharmaceutical product research, development, production, marketing, and distribution. The company&#8217;s product line includes active pharmaceutical ingredients (API) and human formulations. The company&#8217;s stock is listed on the National Stock Exchange [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":11,"featured_media":17793,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false},"categories":[99,679],"tags":[1788,1786,1787],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Cadila Share Price - Live NSE\/BSE Stock Price - Kuvera<\/title>\n<meta name=\"description\" content=\"Check out Cadila Share Price Today. Live NSE\/BSE Cadila Stock Price at Kuvera. Get Live Stock News and Expert Suggestions at Kuvera.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cadila Share Price - Live NSE\/BSE Stock Price - Kuvera\" \/>\n<meta property=\"og:description\" content=\"Check out Cadila Share Price Today. Live NSE\/BSE Cadila Stock Price at Kuvera. Get Live Stock News and Expert Suggestions at Kuvera.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/\" \/>\n<meta property=\"og:site_name\" content=\"Kuvera\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kuvera.in\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-21T12:49:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kuvera.in\/blog\/wp-content\/uploads\/2022\/10\/Cadila-Share-Price.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2240\" \/>\n\t<meta property=\"og:image:height\" content=\"1260\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Kuvera\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Kuvera_In\" \/>\n<meta name=\"twitter:site\" content=\"@Kuvera_In\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kuvera\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cadila Share Price - Live NSE\/BSE Stock Price - Kuvera","description":"Check out Cadila Share Price Today. Live NSE\/BSE Cadila Stock Price at Kuvera. Get Live Stock News and Expert Suggestions at Kuvera.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/","og_locale":"en_US","og_type":"article","og_title":"Cadila Share Price - Live NSE\/BSE Stock Price - Kuvera","og_description":"Check out Cadila Share Price Today. Live NSE\/BSE Cadila Stock Price at Kuvera. Get Live Stock News and Expert Suggestions at Kuvera.","og_url":"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/","og_site_name":"Kuvera","article_publisher":"https:\/\/www.facebook.com\/kuvera.in","article_published_time":"2022-10-21T12:49:15+00:00","og_image":[{"width":2240,"height":1260,"url":"https:\/\/kuvera.in\/blog\/wp-content\/uploads\/2022\/10\/Cadila-Share-Price.png","type":"image\/png"}],"author":"Kuvera","twitter_card":"summary_large_image","twitter_creator":"@Kuvera_In","twitter_site":"@Kuvera_In","twitter_misc":{"Written by":"Kuvera","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#article","isPartOf":{"@id":"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/"},"author":{"name":"Kuvera","@id":"https:\/\/kuvera.in\/blog\/#\/schema\/person\/6b774e7d3516942b9e0242c93d7cb307"},"headline":"Cadila Share Price History and Analysis","datePublished":"2022-10-21T12:49:15+00:00","dateModified":"2022-10-21T12:49:15+00:00","mainEntityOfPage":{"@id":"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/"},"wordCount":2314,"commentCount":0,"publisher":{"@id":"https:\/\/kuvera.in\/blog\/#organization"},"keywords":["Cadila Helathcare Ltd share","Cadila Share Price","Cadila Stock Price"],"articleSection":["Investing 101","Stocks"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/","url":"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/","name":"Cadila Share Price - Live NSE\/BSE Stock Price - Kuvera","isPartOf":{"@id":"https:\/\/kuvera.in\/blog\/#website"},"datePublished":"2022-10-21T12:49:15+00:00","dateModified":"2022-10-21T12:49:15+00:00","description":"Check out Cadila Share Price Today. Live NSE\/BSE Cadila Stock Price at Kuvera. Get Live Stock News and Expert Suggestions at Kuvera.","breadcrumb":{"@id":"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/kuvera.in\/blog\/cadila-share-price-history-and-analysis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kuvera.in\/blog\/"},{"@type":"ListItem","position":2,"name":"Cadila Share Price History and Analysis"}]},{"@type":"WebSite","@id":"https:\/\/kuvera.in\/blog\/#website","url":"https:\/\/kuvera.in\/blog\/","name":"Kuvera","description":"Wealth Management, Simplified","publisher":{"@id":"https:\/\/kuvera.in\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kuvera.in\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kuvera.in\/blog\/#organization","name":"Kuvera","url":"https:\/\/kuvera.in\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kuvera.in\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/kuvera.in\/blog\/wp-content\/uploads\/2022\/07\/cropped-cropped-kuvera-logo-dark-3.png","contentUrl":"https:\/\/kuvera.in\/blog\/wp-content\/uploads\/2022\/07\/cropped-cropped-kuvera-logo-dark-3.png","width":83,"height":13,"caption":"Kuvera"},"image":{"@id":"https:\/\/kuvera.in\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kuvera.in","https:\/\/twitter.com\/Kuvera_In","https:\/\/www.instagram.com\/kuvera.in","https:\/\/www.linkedin.com\/company-beta\/10456535\/"]},{"@type":"Person","@id":"https:\/\/kuvera.in\/blog\/#\/schema\/person\/6b774e7d3516942b9e0242c93d7cb307","name":"Kuvera","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kuvera.in\/blog\/#\/schema\/person\/image\/","url":"https:\/\/kuvera.in\/blog\/wp-content\/uploads\/2019\/07\/social-media-logo-02-alt-v3-150x150.jpg","contentUrl":"https:\/\/kuvera.in\/blog\/wp-content\/uploads\/2019\/07\/social-media-logo-02-alt-v3-150x150.jpg","caption":"Kuvera"},"description":"Kuvera is India's first free Direct Mutual Fund investing platform. We bring you goal-based investing and innovative features like Tax Harvesting, TradeSmart, Family Account and more!","sameAs":["http:\/\/kuvera.in"],"url":"https:\/\/kuvera.in\/blog\/author\/kuvera-research\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/kuvera.in\/blog\/wp-json\/wp\/v2\/posts\/17785"}],"collection":[{"href":"https:\/\/kuvera.in\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kuvera.in\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kuvera.in\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kuvera.in\/blog\/wp-json\/wp\/v2\/comments?post=17785"}],"version-history":[{"count":9,"href":"https:\/\/kuvera.in\/blog\/wp-json\/wp\/v2\/posts\/17785\/revisions"}],"predecessor-version":[{"id":17798,"href":"https:\/\/kuvera.in\/blog\/wp-json\/wp\/v2\/posts\/17785\/revisions\/17798"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kuvera.in\/blog\/wp-json\/wp\/v2\/media\/17793"}],"wp:attachment":[{"href":"https:\/\/kuvera.in\/blog\/wp-json\/wp\/v2\/media?parent=17785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kuvera.in\/blog\/wp-json\/wp\/v2\/categories?post=17785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kuvera.in\/blog\/wp-json\/wp\/v2\/tags?post=17785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}